Showing 1 - 10 of 20
Financial ties between drug companies and medical researchers are thought to bias results published in medical journals. To enable readers to account for such bias, most medical journals require authors to disclose potential conflicts of interest. For such policies to be effective, conflict...
Persistent link: https://www.econbiz.de/10014234349
Financial ties between drug companies and medical researchers are thought to bias studies published in medical journals. To enable readers to account for such bias, most medical journals require authors to disclose potential conflicts of interest. We examine whether disclosure reduces article...
Persistent link: https://www.econbiz.de/10014261656
Financial ties between drug companies and medical researchers are thought to bias results published in medical journals. To enable readers to account for such bias, most medical journals require authors to disclose potential conflicts of interest. For such policies to be effective, conflict...
Persistent link: https://www.econbiz.de/10014264886
Financial ties between drug companies and medical researchers are thought to bias studies published in medical journals. To enable readers to account for such bias, most medical journals require authors to disclose potential conflicts of interest. We examine whether disclosure reduces article...
Persistent link: https://www.econbiz.de/10014226124
Persistent link: https://www.econbiz.de/10001237568
Persistent link: https://www.econbiz.de/10003294372
Persistent link: https://www.econbiz.de/10003234854
"As health care costs continue to rise, governments and private payers are being forced to make difficult coverage decisions about new health care treatments. Cost-effectiveness (CE) analysis is the main method used to prioritize this spending. The self-evident efficiency rationale for CE is...
Persistent link: https://www.econbiz.de/10003850387
Persistent link: https://www.econbiz.de/10009787433
Persistent link: https://www.econbiz.de/10009745391